Continuing Medical Education

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Texas Medical Association (TMA) and the Houston Society of Clinical Pathologists. The Texas Medical Association is accredited by the ACCME to provide continuing medical education for physicians
Credit Designation: The TMA designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Objectives

Diagnosis, Significance and Laboratory Management of tubal Intraepithelial Neoplasia.   
Christopher P. Crum, M.D.

Know the risk of pelvic serous cancer in women with BRCA mutations.

Be able to list the potential mimics of early serous carcinoma in the tube.

Apply an algorithm for evaluating tubal epithelial atypia.

Endocervical Adenocarcinoma: Adenocarcinoma In Situ vs. Invasion and Special Variants.
Teri A. Longacre, M.D.

Identify essential tools for the assessment of cervical glandular lesions;

Apply specific criteria for histologic diagnosis of endocervical adenocarcinoma in situ vs. morphologic mimics;

Be able to utilize new Silva classification system for invasive endocervical adenocarcinoma;

Classify endocervical adenocarcinoma by recently updated WHO subtypes;

Integrate histologic, immunohistochemical and HPV testing results

Uterine Cancer:  Pearls and Pitfalls in Histologic Subtyping.
Joseph T. Rabban, M.D., MPH

Although the histologic subtyping and grading of most uterine cancer is straightforward, a subset of aggressive uterine tumors may simulate more indolent uterine tumors and vice versa.  This may lead to under-treatment or over treatment.  

This lecture offers a pattern-based approach to these types of uterine cancer that can pose the greatest diagnostic challenges.

A practical approach to the use of immunohistochemistry is also offered.

Cervical Cancer Screening in the Era of HPV Vaccination and Primary HPV Screening:
Where Are We Today and Where Do We Go from Here?
Dina Mody, M.D.

Understand similarities and differences between the various HPV testing methodologies currently FDA approved in the USA;

Be familiar with the Types of HPV vaccines currently available in the USA;

Understand risk stratification and the basis for current screening and testing strategies for cervical cancer prevention

Based on vaccination types, consider the potential screening strategies of the future.

Hydatidiform Moles—What You Really Need to Know
Edwina Popek, D.O.

Describe the gross and microscopic features of very early complete hydatidiform mole.

Discuss the use of p57 in the diagnosis of complete hydatidiform mole.

Discuss the features of invasive complete hydatidiform mole.

Discuss the low risk of gestational trophoblastic disease after non-molar and partial molar pregnancy.

Ovarian Germ Cell Tumors: An Update.
Francisco Nogales, M.D.

To review the role of immunohistochemical markers in the proper classification of ovarian germ cell tumors.

To review the several histologic patterns seen in these neoplasm.

Unusual Presentations of Gynecologic Tumors.
Elizabeth D. Euscher, M.D.; Preetha Ramalingam, M.D., and Ramya Masand, M.D.

To discuss the clinicopathologic and immunohistochemical features of some gynecological neoplasms presenting either at unusual locations or demonstrating confounding histological features.

Mullerian Smooth Muscle Tumors that Nobody wants to Talk About.
Anais Malpica, M.D.

To review the histological, immunohistochemical and clinical features of uterine low grade smooth muscle neoplasms associated with extrauterine disease.

To review uterine smooth muscle tumors of uncertain malignant potential.